ArticleBiomacromolecules2025
Broad-Spectrum Antiviral Styrene Maleic-Acid Copolymer Lipid Particle Nanodiscs for pH-Responsive Irreversible Virus Inactivation.
Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.ACS materials letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viruses, such as influenza A virus and SARS-CoV-2, continue to pose significant global health challenges. Current antivirals, which are often specific to a single virus, face limitations due to rapid mutations and the emergence of new strains. In this study, we introduce styrene maleic acid copolymer lipid particle nanodiscs (SMALP-NDs) as a broad-spectrum antiviral platform that employs a dual mode of action. First, SMALP-NDs bind to positively charged viral proteins via their negatively charged surfaces, thereby blocking viral entry. Second, they induce the collapse of viral envelopes under acidic conditions similar to those in the endosome, leading to virus inactivation via a cell-mediated mechanism. SMALP-NDs demonstrated broad-spectrum antiviral activity against influenza A/B and multiple SARS-CoV-2 variants, including Omicron JN.1, as well as herpes simplex virus types 1 and 2 and vaccinia virus, underscoring their versatility. Intranasal administration of SMALP-NDs has successfully protected mice from lethal H1N1 and H5N2 influenza A viruses as well as SARS-CoV-2. These findings underscore that SMALP-NDs effectively counteract the increasing positive charge of emerging viral proteins through their negatively charged surfaces while leveraging pH-responsive virus inactivation mechanisms to achieve high antiviral efficacy with low toxicity, offering a significant advantage over traditional antiviral nanomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.